Concepts (109)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombosis | 3 | 2024 | 199 | 1.000 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2024 | 97 | 1.000 |
Why?
|
| Hemorrhage | 3 | 2024 | 268 | 0.940 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2021 | 47 | 0.870 |
Why?
|
| Hematologic Neoplasms | 1 | 2024 | 49 | 0.820 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 68 | 0.810 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2023 | 108 | 0.800 |
Why?
|
| Rituximab | 2 | 2023 | 88 | 0.770 |
Why?
|
| Androgen Antagonists | 1 | 2018 | 25 | 0.580 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2018 | 17 | 0.580 |
Why?
|
| Multiple Myeloma | 1 | 2023 | 348 | 0.560 |
Why?
|
| Medical Marijuana | 2 | 2025 | 18 | 0.420 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2025 | 193 | 0.360 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 238 | 0.290 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 168 | 0.280 |
Why?
|
| Medical Oncology | 2 | 2025 | 66 | 0.260 |
Why?
|
| Aged | 11 | 2025 | 14469 | 0.240 |
Why?
|
| Humans | 19 | 2025 | 63512 | 0.220 |
Why?
|
| Hemostasis | 1 | 2024 | 18 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2023 | 8 | 0.210 |
Why?
|
| Vincristine | 1 | 2023 | 28 | 0.210 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2025 | 87 | 0.210 |
Why?
|
| Mutation | 2 | 2025 | 2615 | 0.210 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 83 | 0.210 |
Why?
|
| Prednisone | 1 | 2023 | 85 | 0.210 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2025 | 172 | 0.210 |
Why?
|
| Doxorubicin | 1 | 2023 | 100 | 0.200 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 676 | 0.200 |
Why?
|
| Female | 12 | 2025 | 32912 | 0.200 |
Why?
|
| Cell Cycle Proteins | 1 | 2025 | 396 | 0.190 |
Why?
|
| Anticoagulants | 2 | 2024 | 496 | 0.190 |
Why?
|
| Hematology | 1 | 2022 | 12 | 0.190 |
Why?
|
| Graft vs Host Disease | 1 | 2023 | 113 | 0.190 |
Why?
|
| Male | 12 | 2025 | 29927 | 0.190 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2024 | 228 | 0.190 |
Why?
|
| Quarantine | 1 | 2021 | 11 | 0.170 |
Why?
|
| Curriculum | 1 | 2025 | 600 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 346 | 0.170 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 352 | 0.160 |
Why?
|
| Chordoma | 1 | 2020 | 6 | 0.160 |
Why?
|
| Immunotherapy | 2 | 2020 | 256 | 0.160 |
Why?
|
| Neoplasms | 2 | 2021 | 1364 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 449 | 0.160 |
Why?
|
| Infection Control | 1 | 2021 | 106 | 0.160 |
Why?
|
| Spinal Neoplasms | 1 | 2020 | 17 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 774 | 0.150 |
Why?
|
| Hepatitis | 1 | 2019 | 57 | 0.150 |
Why?
|
| Betacoronavirus | 1 | 2020 | 182 | 0.140 |
Why?
|
| Middle Aged | 6 | 2025 | 17641 | 0.140 |
Why?
|
| Kidney Neoplasms | 2 | 2019 | 160 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 209 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 223 | 0.130 |
Why?
|
| Risk Assessment | 1 | 2024 | 2082 | 0.130 |
Why?
|
| Patient Discharge | 1 | 2020 | 512 | 0.130 |
Why?
|
| Melanoma | 1 | 2020 | 331 | 0.130 |
Why?
|
| Risk Factors | 2 | 2024 | 5359 | 0.130 |
Why?
|
| Adult | 5 | 2025 | 16837 | 0.130 |
Why?
|
| Urothelium | 1 | 2015 | 22 | 0.110 |
Why?
|
| Breast Neoplasms | 1 | 2023 | 1198 | 0.110 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2015 | 105 | 0.110 |
Why?
|
| Prognosis | 3 | 2025 | 1749 | 0.100 |
Why?
|
| Treatment Outcome | 1 | 2024 | 5699 | 0.100 |
Why?
|
| Acute Kidney Injury | 1 | 2015 | 141 | 0.100 |
Why?
|
| Aged, 80 and over | 4 | 2025 | 5471 | 0.090 |
Why?
|
| Cohort Studies | 2 | 2023 | 2574 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2023 | 6670 | 0.060 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 663 | 0.050 |
Why?
|
| Clone Cells | 1 | 2023 | 114 | 0.050 |
Why?
|
| Abatacept | 1 | 2023 | 65 | 0.050 |
Why?
|
| Steroids | 1 | 2023 | 55 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2025 | 313 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2025 | 572 | 0.050 |
Why?
|
| Young Adult | 2 | 2025 | 4700 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 287 | 0.050 |
Why?
|
| Pleural Neoplasms | 1 | 2021 | 18 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 108 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2021 | 88 | 0.040 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2021 | 44 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 200 | 0.040 |
Why?
|
| Hoarseness | 1 | 2020 | 1 | 0.040 |
Why?
|
| CTLA-4 Antigen | 1 | 2020 | 72 | 0.040 |
Why?
|
| Imatinib Mesylate | 1 | 2020 | 34 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 753 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 57 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 378 | 0.040 |
Why?
|
| Bone Neoplasms | 1 | 2021 | 125 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 374 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2022 | 353 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2023 | 1007 | 0.040 |
Why?
|
| Survival Rate | 1 | 2021 | 851 | 0.040 |
Why?
|
| Palliative Care | 1 | 2021 | 230 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 168 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2019 | 114 | 0.040 |
Why?
|
| Pulmonary Embolism | 1 | 2020 | 174 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2021 | 297 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2019 | 103 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 310 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 1120 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 144 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 2681 | 0.030 |
Why?
|
| Incidence | 1 | 2020 | 1380 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 673 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 2462 | 0.030 |
Why?
|
| Time Factors | 1 | 2021 | 3770 | 0.030 |
Why?
|
| Hospitalization | 1 | 2020 | 1364 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 980 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 2173 | 0.020 |
Why?
|
| United States | 1 | 2023 | 7855 | 0.020 |
Why?
|
| Adolescent | 1 | 2020 | 6248 | 0.020 |
Why?
|